Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
- Conditions
- NAFLD (Non-alcoholic Fatty Liver Disease)NASH (Nonalcoholic Steatohepatitis)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07128797
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University, Beijing, Beijing, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Sinopharm Tongmei General Hospital, Datong, Shanxi, China
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06838546
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou, Hanzhou, China
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical CancersSmall Cell Lung CancerHepatocellular Carcinoma (HCC)Colorectal CancerNon-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06724263
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 1552
- Registration Number
- NCT05700591
- Locations
- 🇨🇳
Xuancheng People's Hospital, Xuancheng, Anhui, China
🇨🇳Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05655221
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Inc., Glendale, California, United States
- Prev
- 1
- 2
- Next